Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Return on Sales (2020 - 2026)

Opus Genetics has reported Return on Sales over the past 9 years, most recently at 0.3% for Q1 2026.

  • Quarterly Return on Sales fell 29.0% to 0.3% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.09% through Mar 2026, down 5.0% year-over-year, with the annual reading at 0.03% for FY2025, 2.0% up from the prior year.
  • Return on Sales was 0.3% for Q1 2026 at Opus Genetics, down from 0.04% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q4 2022 and troughed at 0.45% in Q2 2022.
  • The 5-year median for Return on Sales is 0.04% (2024), against an average of 0.1%.
  • Year-over-year, Return on Sales skyrocketed 97bps in 2022 and then decreased -29bps in 2026.
  • A 5-year view of Return on Sales shows it stood at 0.01% in 2022, then tumbled by -433bps to 0.03% in 2023, then crashed by -188bps to 0.08% in 2024, then skyrocketed by 48bps to 0.04% in 2025, then crashed by -611bps to 0.3% in 2026.
  • Per Business Quant, the three most recent readings for IRD's Return on Sales are 0.3% (Q1 2026), 0.04% (Q4 2025), and 0.06% (Q3 2025).